FDA Determines Regulatory Review Period for SABRIL Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for SABRIL, a human drug product, in accordance with federal regulations, following a patent extension application submitted to the US Department of Commerce